In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

VEOCELtm, the flagship specialty nonwovens brand of Lenzing Group, highlighted its commitment to innovation and providing solutions to help address the global plastic crisis at the "SEA of Solutions ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make ...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda ... to be known under the brand name of Ontruzant and ...

In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...